Volume | 154,924 |
|
|||||
News | - | ||||||
Day High | 12.18 | Low High |
|||||
Day Low | 10.44 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Boundless Bio Inc | BOLD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.80 | 10.44 | 12.18 | 12.07 | 11.03 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,938 | 154,924 | $ 11.44 | $ 1,772,358 | - | 9.83 - 15.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:04 | 1,651 | $ 12.07 | USD |
Boundless Bio Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.78B | 311.79M | - | 0 | -49.43M | -0.16 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Boundless Bio News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BOLD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.30 | 12.18 | 9.83 | 10.59 | 153,218 | 0.77 | 6.81% |
1 Month | 14.25 | 15.20 | 9.83 | 12.59 | 245,161 | -2.18 | -15.30% |
3 Months | 14.25 | 15.20 | 9.83 | 12.59 | 245,161 | -2.18 | -15.30% |
6 Months | 14.25 | 15.20 | 9.83 | 12.59 | 245,161 | -2.18 | -15.30% |
1 Year | 14.25 | 15.20 | 9.83 | 12.59 | 245,161 | -2.18 | -15.30% |
3 Years | 14.25 | 15.20 | 9.83 | 12.59 | 245,161 | -2.18 | -15.30% |
5 Years | 40.32 | 60.00 | 9.83 | 46.04 | 670,800 | -28.25 | -70.06% |
Boundless Bio Description
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. |